MTOR is an inclusion criterion in 21 clinical trials for malignant solid tumor, of which 17 are open and 4 are closed. Of the trials that contain MTOR status and malignant solid tumor as inclusion criteria, 7 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), and 11 are phase 2 (10 open) [4].

MTOR is an inclusion criterion in 8 clinical trials for breast carcinoma, of which 8 are open and 0 are closed. Of the trials that contain MTOR status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [4].

MTOR is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain MTOR status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MTOR status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (1 open) [4].

MTOR is an inclusion criterion in 3 clinical trials for cancer, of which 1 is open and 2 are closed. Of the trials that contain MTOR status and cancer as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), and 1 is phase 2 (0 open) [4].

MTOR is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain MTOR status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain MTOR status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

MTOR is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain MTOR status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MTOR status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

MTOR is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [4].

MTOR is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

MTOR is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains MTOR status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MTOR is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].